Net loss for the nine months ended September 30, 2016 was $81.62 million, compared to $29.85 million for the nine months ended September 30, 2015. Financial Summary About BeiGene BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer.